Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
Por:
Han YJ, Lee KH, Yoon S, Nam SW, Ryu S, Seong D, Kim JS, Lee JY, Yang JW, Lee J, Koyanagi A, Hong SH, Dragioti E, Radua J, Smith L, Oh H, Ghayda RA, Kronbichler A, Effenberger M, Kresse D, Denicolò S, Kang W, Jacob L, Shin H and Shin JI
Publicada:
1 ene 2021
Ahead of Print:
1 ene 2021
Categoría:
Medicine (miscellaneous)
Resumen:
Rationale: Coronavirus disease 2019 (COVID-19) has spread worldwide and poses a threat to humanity. However, no specific therapy has been established for this disease yet. We conducted a systematic review to highlight therapeutic agents that might be effective in treating COVID-19. Methods: We searched Medline, Medrxiv.org, and reference lists of relevant publications to identify articles of in vitro, in vivo, and clinical studies on treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19 published in English until the last update on October 11, 2020. Results: We included 36 studies on SARS, 30 studies on MERS, and 10 meta-analyses on SARS and MERS in this study. Through 12,200 title and 830 full-text screenings for COVID-19, eight in vitro studies, 46 randomized controlled trials (RCTs) on 6,886 patients, and 29 meta-analyses were obtained and investigated. There was no therapeutic agent that consistently resulted in positive outcomes across SARS, MERS, and COVID-19. Remdesivir showed a therapeutic effect for COVID-19 in two RCTs involving the largest number of total participants (n = 1,461). Other therapies that showed an effect in at least two RCTs for COVID-19 were sofosbuvir/daclatasvir (n = 114), colchicine (n = 140), IFN-ß1b (n = 193), and convalescent plasma therapy (n = 126). Conclusions: This review provides information to help establish treatment and research directions for COVID-19 based on currently available evidence. Further RCTs are required.
Filiaciones:
Han YJ:
Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
Lee KH:
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea
Yoon S:
Yonsei University College of Medicine, Seoul, Republic of Korea
Nam SW:
Department of Rheumatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
Ryu S:
Yonsei University College of Medicine, Seoul, Republic of Korea
Seong D:
Yonsei University College of Medicine, Seoul, Republic of Korea
Kim JS:
Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
Lee JY:
Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
Yang JW:
Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
Lee J:
Department of Psychiatry, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
Koyanagi A:
Research and development unit, Parc Sanitari Sant Joan de Déu/CIBERSAM, Universitat de Barcelona, Fundació Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
ICREA, Pg. Lluís Companys 23, 08010, Barcelona, Spain
Hong SH:
Department of Global Health and Population, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, USA
Dragioti E:
Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden
Radua J:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Mental Health Research Networking Center (CIBERSAM), Barcelona, Spain
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Smith L:
The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
Oh H:
School of Social Work, University of Southern California, CA, USA
Ghayda RA:
Department of Global Health and Population, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, USA
Division of Urology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Kronbichler A:
Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria
Effenberger M:
Department of Internal Medicine I (Gastroenterology, Hepatology, Endocrinology & Metabolism), Medical University Innsbruck, Innsbruck, Austria
Kresse D:
Department of Internal Medicine, St. Johann County Hospital, St. Johann in Tirol, Austria
Denicolò S:
Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria
Kang W:
Department of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA
Jacob L:
Research and development unit, Parc Sanitari Sant Joan de Déu/CIBERSAM, Universitat de Barcelona, Fundació Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France
Shin H:
Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
Shin JI:
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea
Green Published, Green Accepted, gold
|